|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2022―May―07 |
Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic |
Émilien Schultz, Léo Mignot, Jeremy Ward, Daniela Boaventura, Christian Chabannon, Julien Mancini |
2 |
[GO] |
2022―Apr―27 |
Adverse drug reactions and ivermectin in COVID-19 |
Jean-Louis Montastruc |
3 |
[GO] |
2022―Apr―26 |
Cluster headache after COVID-19 vaccination with Comirnaty: a signal in pharmacovigilance database* |
Michaël Rochoy, Eric Billy, Franck Clarot, Victor Dumortier, Sophie Gautier, Romain Barus |
4 |
[GO] |
2022―Apr―20 |
Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO’s pharmacovigilance database |
Jeremy T. Campillo, Jean-Luc Faillie |
5 |
[GO] |
2022―Apr―20 |
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) |
Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard, et al. (+12) Sihem Benaboud, Laurent Chouchana, Jean-Luc Cracowski, Milou-Daniel Drici, Rodolphe Garraffo, Romain Guilhaumou, Annie-Pierre Jonville-Bera, Mathieu Molimard, Patric Muret, Gilles Peytavin, Vincent Richard, Caroline Solas |
6 |
[GO] |
2021―Dec―28 |
Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic |
Pauline Lory, Jeffrey Lombardi, Clémence Lacroix, Paola Sanchez-Pena, Serena Romani, Aurélie Grandvuillemin |
7 |
[GO] |
2021―Dec―04 |
Lessons from the COVID-19 pandemic |
Philippe Lechat |
8 |
[GO] |
2021―Oct―25 |
A historical cohort stuy to investigation of statins safety in COVID-19 hospitalized patients |
Saeed Nateghi, Mohammad Mahmoudi Gomari, Hadiseh Hosamirudsari, Behnam Behnoush, Asma Razmjoofard, Goli Azimi, et al. (+3) Shokooh Ordookhani, Ali Jafarpour, Neda Faraji |
9 |
[GO] |
2021―Oct―08 |
Peptides-based therapeutics: emerging potential therapeutic agents for COVID-19 |
Jagat Narayan Shah, Guang-Qin Guo, Anand Krishnan, Muthusamy Ramesh, Naresh Kumar Katari, Mohd Shahbaaz, et al. (+3) Magda H. Abdellattif, Sachin Kumar Singh, Kamal Dua |
10 |
[GO] |
2021―Jul―27 |
Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against SARS-CoV-2 and the urgent need of a large immunization in healthcare workers |
Laurent Chouchana, Etienne Canouï, Rui Batista, Adrien Contejean, Alain Cariou, Jean Marc Treluyer, Caroline Charlier |
11 |
[GO] |
2021―Jun―01 |
COVID-19 vaccines and pregnancy: what do we know? |
Judith Cottin, Justine Benevent, Sophie Khettar, Isabelle Lacroix |
12 |
[GO] |
2021―May―28 |
COVID-19 vaccines: a perspective from social pharmacology |
Jean-Louis Montastruc, Margaux Lafaurie, Claire de Canecaude, François Montastruc, Haleh Bagheri, Geneviève Durrieu, Agnès Sommet |
13 |
[GO] |
2021―May―28 |
COVID-19: Pharmacology has kept the science ship running during the storm |
Mathieu Molimard, Vincent Richard, Jean-Luc Cracowski |
14 |
[GO] |
2021―May―12 |
Efficacy of Covid-19 vaccines: from clinical trials to real life |
Dominique Deplanque, Odile Launay |
15 |
[GO] |
2021―May―07 |
French organization for the Pharmacovigilance of COVID-19 vaccines: a major challenge |
Clémence Lacroix, Francesco Salvo, Valérie Gras-Champel, Sophie Gautier, Nathalie Massy, Marie-Blanche Valnet-Rabier, et al. (+6) Aurélie Grandvuillemin, Céline Mounier, Mehdi Benkebil, Antoine Pariente, Annie-Pierre Jonville-Bera, Joëlle Micallef |
16 |
[GO] |
2021―May―07 |
Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects |
Antoine Pariente, Julien Bezin |
17 |
[GO] |
2021―Apr―29 |
Eruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19* |
Nihal Bekkali, Tanguy Allard, Eric Estève, Céline Lengellé |
18 |
[GO] |
2021―Apr―02 |
Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy |
Thomas Soeiro, Francesco Salvo, Antoine Pariente, Aurélie Grandvuillemin, Annie-Pierre Jonville-Béra, Joëlle Micallef |
19 |
[GO] |
2021―Mar―06 |
Pneumopathie médicamenteuse ou liée à la COVID-19: un train peut en cacher un autre! |
Mélanie Vasseur, Marine Tambon, Mireille Gony, Nicolas Lebrun, Haleh Bagheri |
20 |
[GO] |
2021―Feb―16 |
Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19 |
Zineb Ghrieb, Souhil Allaoua, Jin Huang, Nathalie Langner, Florène François, Corinne Maréchal, et al. (+8) Majdi Jebali, Céleste Lebbé, Abdennour Chellah, Anne Bergeron, Jean-Jacques Kiladjian, Rafael Daltro De Oliveira, Juliette Soret-Dulphy, Lina Benajiba |
21 |
[GO] |
2021―Jan―28 |
Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19 |
Noël Zahr, Saik Urien, Benoit Llopis, Valérie Pourcher, Olivier Paccoud, Alexandre Bleibtreu, et al. (+11) Julien Mayaux, Estelle Gandjbakhch, Guillaume Hekemian, Alain Combes, Olivier Benveniste, David Saadoun, Yves Allenbach, Bruno Pinna, Patrice Cacoub, Christian Funck-Brentano, Joe-Elie Salem |
22 |
[GO] |
2021―Jan―20 |
Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center |
Mathieu Chappuy, Marie Peyrat, Olivier Lejeune, Nathalie Duvernay, Brigitte David, Philippe Joubert, Philippe Lack |
23 |
[GO] |
2021―Jan―19 |
DPP-4 inhibitors and severe course of illness in patients with COVID-19 |
Béatrice Bouhanick, Jean-Luc Cracowski, Jean-Luc Faillie |
24 |
[GO] |
2020―Dec―26 |
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19 |
Chia Siang Kow, Syed Shahzad Hasan |
25 |
[GO] |
2020―Nov―01 |
Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? |
Shivshankar Malkarjun Gunjegaonkar, Thukani Sathanantham Shanmugarajan, Mohanasundaram Arunsundar, Uppuluri Varuna Naga Venkata Arjun, Kadirrel Devi, Sagar Baliram Wankhede, Velayutham Ravichandiran |
26 |
[GO] |
2020―Oct―17 |
Modifications pharmacocinétiques liées à une infection aigue. Exemples issus de la pandémie de SARS-Cov2 |
Anaëlle Chavant, Elodie Gautier-Veyret, Stéphanie Chhun, Romain Guilhaumou, Françoise Stanke-Labesque |
27 |
[GO] |
2020―Jul―22 |
COVID-19 and NSAIDs: Primum non nocere |
Joëlle Micallef, Thomas Soeiro, Annie-Pierre Jonville Béra |
28 |
[GO] |
2020―Jul―12 |
No arguments for extra risk from ibuprofen in SARS-COV2 infection |
Nicholas Moore |
29 |
[GO] |
2020―Jun―27 |
NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection |
Medine Cumhur Cure, Adem Kucuk, Erkan Cure |
30 |
[GO] |
2020―Jun―27 |
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: a review |
Lucile Grange, Philippe Guilpain, Marie-Elise Truchetet, Jean-Luc Cracowski |
31 |
[GO] |
2020―Jun―23 |
Addictovigilance contribution during COVID-19 epidemic and lockdown in France |
Maryse Lapeyre-Mestre, Alexandra Boucher, Amelie Daveluy, Valerie Gibaja, Emilie Jouanjus, Michel Mallaret, et al. (+2) Helene Peyrière, Joëlle Micallef |
32 |
[GO] |
2020―Jun―06 |
Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic |
Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard |
33 |
[GO] |
2020―May―23 |
Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence |
Matthieu Roustit, Romain Guilhaumou, Mathieu Molimard, Milou Drici, Silvy Laporte, Jean-Louis Montastruc |
34 |
[GO] |
2020―May―20 |
Renin-angiotensin-aldosterone system and COVID-19 infection |
Joachim Alexandre, Jean-Luc Cracowski, Vincent Richard, Béatrice Bouhanick |
35 |
[GO] |
2020―May―15 |
Diabetes and COVID-19 |
Béatrice Bouhanick, Jean Luc Cracowski, Jean Luc Faillie |
36 |
[GO] |
2020―May―15 |
Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France |
François Montastruc, Charles Romano, Jean-Louis Montastruc, Stein Silva, Thierry Seguin, Vincent Minville, et al. (+3) Bernard Georges, Béatrice Riu-Poulenc, Olivier Fourcade |
37 |
[GO] |
2020―May―07 |
Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection |
Joëlle Micallef, Thomas Soeiro, Jonville-Béra Annie-Pierre |
38 |
[GO] |
2020―May―07 |
“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers |
Alexandre Gérard, Serena Romani, Audrey Fresse, Delphine Viard, Nadège Parassol, Aurélie Granvuillemin, et al. (+3) Laurent Chouchana, Fanny Rocher, Milou-Daniel Drici |
39 |
[GO] |
2020―May―05 |
Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data |
Aurélie Grandvuillemin, Audrey Fresse, Clément Cholle, Samir Yamani, Anne Dautriche |